JAGSNPHARM.BOJAGSNPHARM.BO
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
16.48%
↓ 90% below average
Average (39q)
159.23%
Historical baseline
Range
High:2719.47%
Low:-617.37%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 16.48% |
| Q2 2025 | 63.98% |
| Q1 2025 | -79.42% |
| Q4 2024 | 179.17% |
| Q3 2024 | 115.03% |
| Q2 2024 | 50.15% |
| Q1 2024 | -10.45% |
| Q4 2023 | -46.96% |
| Q3 2023 | -0.09% |
| Q2 2023 | 33.50% |
| Q1 2023 | -28.04% |
| Q4 2022 | -25.23% |
| Q3 2022 | 2719.47% |
| Q2 2022 | 1377.20% |
| Q1 2022 | -99.54% |
| Q4 2021 | -26.01% |
| Q3 2021 | 6.71% |
| Q2 2021 | 34.31% |
| Q1 2021 | -6.10% |
| Q4 2020 | 35.46% |
| Q3 2020 | 59.06% |
| Q2 2020 | 62.10% |
| Q1 2020 | -31.90% |
| Q4 2019 | 12.52% |
| Q3 2019 | 1.27% |
| Q2 2019 | -32.64% |
| Q1 2019 | 70.53% |
| Q4 2018 | -1.45% |
| Q3 2018 | 143.35% |
| Q2 2018 | 159.15% |
| Q1 2018 | 45.28% |
| Q4 2017 | 41.69% |
| Q3 2017 | 8.70% |
| Q2 2017 | -617.37% |
| Q1 2017 | -91.76% |
| Q4 2016 | 1867.85% |
| Q3 2016 | -21.53% |
| Q2 2016 | -67.95% |
| Q1 2016 | 473.22% |
| Q4 2015 | -20.39% |